AR
Arvinas, Inc.
ARVN · NASDAQ
$9.39 +0.86% (+$0.08)
1M +4.45%
Market Cap $605.9M
P/E Ratio 65.15x
Div. Yield -
ROE 1.91%
Piotroski F-Score Moderate
6/9Valuation
27 /100
Expensive EV/EBITDA 179.16x
P/S 1.91x
P/B 1.08x
Growth
78 /100
Growing Book val. growth 8.43%
Rev. growth 25.96%
FCF growth N/A
Profitability
25 /100
Weak Net margin 2.94%
Op. margin 4.45%
FCF margin 65.93%
Quality
10 /100
Poor ROE 1.91%
ROA 1.38%
Asset turnover 0.47x
Debt
100 /100
Low Current ratio 7.91x
Net debt/EBITDA -29.76x
Debt/Equity 0.01x
Stability
17 /100
Unstable Rev. volatility 149.04%
EPS volatility 46.61%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ARVN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Randy Teel
Employees
246
Headquarters
New Haven
Upcoming events
04 NOV
Earnings
Upcoming earnings report